全身性紅斑狼瘡病患間COVID-19疫苗接種率的性別差異：疫苗接受模式之時間性分析

Gender Disparities in COVID-19 Vaccination Uptake Among Systemic Lupus Erythematosus Patients: A Temporal Analysis of Vaccine Acceptance Patterns

目的：探討全身性紅斑狼瘡病患間COVID-19疫苗接種模式的性別差異，並找出疫苗接受度及時程的差異。
方法：本單一中心回溯性研究透過電話訪談和病歷審查，分析564位SLE病患（包含526位女性和38位男性）從2021年1月1日至2024年6月28日的COVID-19疫苗接種情況。統計分析檢視兩性間疫苗劑次、種類及時程的差異。
結果：兩組的整體疫苗接種率均很高（女性94.3%、男性97.4%），且所接受的總劑次無顯著差異（女性平均3.33±1.03劑、男性平均3.22±0.98劑）。兩性皆以RNA疫苗為主要選擇。值得注意的是，2021年的疫苗接種時程出現顯著的性別差異：67.7%的女性在7月至9月間接種第一劑疫苗，而50.0%的男性則展現較高的延遲施打比率，並傾向將疫苗接種延至後幾個季度。
結論：雖然兩性之間的整體疫苗接種率相當高，但時間性分析顯示初始疫苗接種模式存在顯著差異，男性在尋求疫苗接種方面較為延遲。這些發現突顯了在全身性紅斑狼瘡病患未來疫苗策略中，發展針對性別之方法的重要性。

Objective: To investigate gender-based differences in COVID-19 vaccine uptake patterns among patients with Systemic Lupus Erythematosus (SLE) and identify disparities in vaccine acceptance and timing.
Methods: A single-center retrospective study analyzed COVID-19 vaccination data from 564 SLE patients (526 women, 38 men) through chart review and telephone interviews to assess COVID-19 vaccination uptake from January 1, 2021, to June 28, 2024. Statistical analyses examined differences in vaccination doses, types, and timing between gender groups.
Results: The overall vaccination rate was high in both groups (94.3% women, 97.4% men), with no significant difference in total doses received (average 3.33±1.03 women, 3.22±0.98 men). RNA-based vaccines were the predominant choice for both genders. Notably, significant gender differences emerged in vaccination timing during 2021, with 67.7% of women receiving their first dose during July-September compared to 50.0% of men, who showed greater initial hesitancy and tended to delay vaccination until later quarters.
Conclusions: While overall vaccination rates were similarly high between genders, temporal analysis revealed significant differences in initial vaccine uptake patterns, with men demonstrating more delayed in seeking vaccination. These findings highlight the importance of developing gender-specific approaches for future vaccination strategies in SLE patients.